Correlation between DAS-28 and neopterin as a biochemical marker of immune system activation in early rheumatoid arthritis

Autoimmunity

Volumn 46, Issue 1, 2013, Pages 44-49

  D'agostino, Liliana Elena ^a   Ventimiglia, Fernando ^a   Verna, Juan Antonio ^a   Colina, Amelia De La ^a   Aguirre, Yanina ^b   Arturi, Alfredo ^b   Capparelli, Alberto ^c  

^a Laboratorio de Análisis Clínicos e Inmunológicos   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^c INSTITUTO DE INVESTIGACIONES FISICOQUÍMICAS TEÓRICAS Y APLICADAS INIFTA   (Argentina)

Author keywords

C reactive protein; DAS 28; Immune activation; Neopterin; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; NEOPTERIN; RHEUMATOID FACTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; MALE; NEOPTERIN BLOOD LEVEL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TURBIDIMETRY;

ADULT; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; NEOPTERIN; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; RHEUMATOID FACTOR; STATISTICS, NONPARAMETRIC;

EID: 84872189415     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.722143     Document Type: Article

References (26)

1. Firestein, G. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361. (Pubitemid 40852711)
2. Murr, C., B. Widner, B. Wirleitner, and D. Fuchs. 2002. Neopterin as a marker for immune system activation. Curr. Drug Metabol. 3: 175-187. (Pubitemid 34326529)
3. Schroecksnadel, K., S. Kaser, M. Ledochowski, et al. 2003. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis. J. Rheumatol. 30: 1935-1939. (Pubitemid 37075539)
4. Berdowska, A., and K. Zwirska-Korczala. 2001. Neopterin measurement in clinical diagnosis. J. Clin. Pharm. Therap. 26: 319-329. (Pubitemid 32989554)
5. Schroecksnadel, K., C. Murr, C. Winkler, et al. 2004. Neopterin to monitor clinical pathologies involving IFN-g production. Pteridines 15: 75-90. (Pubitemid 39280257)
6. Honlinger, M., D. Fuchs, A. Hausen, et al. 1989. Serum neopterin determination for the additional safeguarding of blood transfusions. Our experiences with 76,587 blood donors. Dtsch. Med. Wochenschr. 114: 172-176. (Pubitemid 19053394)
7. Micha Nübling, C., M. Chudy, P. Volkers, and J. Löwer. 2006. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection. Transfusion 46: 1886-1891.
8. Hoffmann, G., and W. Schobersberger. 2004. Neopterin: A mediator of the cellular immune system. Pteridines 15: 107-112. (Pubitemid 39280261)
9. Westermann, J., F. Thiemann, L. Gerstner, et al. 2000. Evaluation of a new simple and rapid enzyme-linked immunosorbent assay kit for neopterin determination. Clin. Chem. Lab. Med. 38: 345-353. (Pubitemid 30444963)
10. Visser, H. 2005. Early diagnosis of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 19: 55-72.
11. Prevoo, M. L., P. L. C. M. Van Riel, M. A. Van't Hof, et al. 1995. Modified disease activity scores that include twenty-Eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38: 44-48.
12. Aziz, N., P. Nishanian, and J. L. Fahey. 1998. Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: Quality controls procedures. Clin. Diagn. Lab. Immunol. 5: 755-761. (Pubitemid 28519247)
13. Mallya, R. K., F. C. de Beer, H. Berry, et al. 1982. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-Reactive protein and erythrocyte sedimentation rate. J. Rheumatol. 9: 224-228. (Pubitemid 12014862)
14. Vogt, B., B. Führnrohr, R. Müller, and A. Sheriff. 2007. CRP and the disposal of dying cells: Consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity 40: 295-298. (Pubitemid 46845524)
15. McInnes, I. B., and G. Schett. 2011. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365: 2205-2219.
16. Berdowska, A., and K. Zwirska-Korczala. 2001. Neopterin measurement in clinical diagnosis. J. Clin. Pharm. Therap. 26: 319-329. (Pubitemid 32989554)
17. Razumovitch, J. A., G. N. Semenkova, D. Fuchs, and S. N. Cherenkevich. 2003. Influence of neopterin on the generation of reactive oxygen species in human neutrophils. FEBS Lett. 549: 83-86. (Pubitemid 36959849)
18. Wirleitner, B., K. Schroecksnadel, C. Winkler, and D. Fuchs. 2005. Neopterin in HIV-1 infection. Mol. Immunol. 42: 183-194. (Pubitemid 39361448)
19. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442. (Pubitemid 46834849)
20. Choy, E. H., and G. S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 33: 222-230.
21. Renaudineau, Y., C. Jamin, A. Saraux, and P. Youinou. 2005. Rheumatoid factor on a daily basis. Autoimmunity 38: 11-16. (Pubitemid 40514998)
22. Vincent, C., L. Nogueira, C. Clavel, M. Sebbag, and G. Serre. 2005. Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 38: 17-24. (Pubitemid 40514999)
23. Syversen, S. W., P. I. Gaarder, G. L. Goll, et al. 2008. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: Results from a 10-year longitudinal study. Ann. Rheum. Dis. 67: 212-217. (Pubitemid 351183310)
24. Maddali Bongi, S., R. Manetti, D. Melchiorre, et al. 2004. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 37: 495-501. (Pubitemid 40123420)
25. Agrawal, S., R. Misra, and A. Aggarwal. 2007. Autoantibodies in rheumatoid arthritis: Association with severity of disease in established RA. Clin. Rheumatol. 26: 201-204. (Pubitemid 46020244)
26. Kurz, K., M. Herold, C. Winkler, et al. 2011. Effects of adalimumab therapy on disease activity and interferong-Mediated biochemical pathways in patients with rheumatoid arthritis. Autoimmunity 44: 235-242.